Anti-robo4 antibodies and uses therefor

Abstract

The invention provides anti-Robo4 antibodies, and compositions comprising the antibodies and methods of using these antibodies, including diagnostic and therapeutic methods.

1 - 24 . (canceled) 
     
     
         25 . A method of in vivo imaging, the method, the method comprising administering an to a mammal an isolated Robo4 antibody comprising
 (i) HVR-L1 comprising SEQ ID NO:1;   (ii) HVR-L2 comprising SEQ ID NO:2;   (iii) HVR-L3 comprising SEQ ID NO:3;   (iv) HVR-H1 comprising SEQ ID NO:17;   (v) HVR-H2 comprising SEQ ID NO:18; and   (vi) HVR-H3 comprising SEQ ID NO:19.   
     
     
         26 . The method of  claim 25 , wherein the mammal is a human. 
     
     
         27 . The method of  claim 25 , wherein the mammal is suspected of having a disease or disorder selected from the group consisting of: cancer, atherosclerosis, retrolental fibroplasia, hemangiomas, chronic inflammation, intraocular neovascular diseases, proliferative retinopathies, diabetic retinopathy, age-related macular degeneration (AMD), neovascular glaucoma, immune rejection of transplanted corneal tissue, rheumatoid arthritis, psoriasis, and combinations thereof. 
     
     
         28 . The method of  claim 25 , wherein the antibody comprises a light chain variable domain comprising an amino acid sequence selected from the group consisting of: SEQ ID NOS:72-97 as shown in  FIGS. 1A and 2A . 
     
     
         29 . The method of  claim 25 , wherein the antibody comprises a heavy chain variable domain comprising an amino acid sequence selected from the group consisting of: SEQ ID NOS:140-165 as shown in  FIGS. 1B and 2B . 
     
     
         30 . The method of  claim 25 , wherein the antibody comprises a light chain variable domain comprising
 an HVR-L1 comprising SEQ ID NO:1,   an HVR-L2 comprising SEQ ID NO:2, and   an HVR-L3 comprising SEQ ID NO:20.   
     
     
         31 . The method of  claim 25 , wherein the antibody comprises a heavy chain variable domain comprising
 an HVR-H1 comprising SEQ ID NO:17,   an HVR-H2 comprising SEQ ID NO:18, and   an HVR-H3 comprising SEQ ID NO:19.   
     
     
         32 . The method of  claim 25 , wherein the antibody comprises
 (i) a light chain variable domain comprising   an HVR-L1 comprising SEQ ID NO:1,   an HVR-L2 comprising SEQ ID NO:2, and   an HVR-L3 comprising QQSRSDHPT (SEQ ID NO:20); and   (ii) a heavy chain variable domain comprising   an HVR-H1 comprising SEQ ID NO:17,   an HVR-H2 comprising SEQ ID NO:18, and   an HVR-H3 comprising SEQ ID NO:19.   
     
     
         33 . The method of  claim 25 , wherein the antibody is selected from the group consisting of a Fab, a Fab′, and a (Fab′) 2 . 
     
     
         34 . The method of  claim 25 , wherein the antibody further comprises a detectable label. 
     
     
         35 . The method of  claim 34 , wherein the detectable label is selected from the group consisting of: biotin, a fluorescent dye, a radionuclide, chelating agent 1, 4, 7, 10-tetraazacyclododecane-N,N′, N″, N′″-tetraacetic acid (DOTA), a microbubble, a perfluorocarbon nanoparticle emulsion, a metallic particle, and combinations thereof. 
     
     
         36 . The antibody of  claim 34 , wherein the detectable label is covalently attached to the antibody at a cysteine residue. 
     
     
         37 . The antibody of  claim 36 , wherein the cysteine residue is at position 118 of the heavy chain Fc region according to EU numbering.